PrimeCog: Primary Care Cognitive Testing

NCT ID: NCT06346535

Last Updated: 2024-04-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2029-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The PrimeCog study aims to describe the symptomatology and pathophysiology of stress-induced exhaustion disorder (SED) and major depressive disorder (MDD) compared to healthy controls (HC). The participants will be recruited at primary care centers, and samples of blood, saliva, and hair will be collected. Digital questionnaires covering psychosocial variables and screening instruments for the detection of depression, anxiety, etc., along with a digital cognitive test battery, will be performed at home. Subsequently, an MRI of the brain will be performed, and analysis of biomarkers for stress, inflammation, and neurodegeneration will be conducted. These procedures will be repeated after twelve and twenty-four months. The study will investigate differences in the biomarkers, neuroimaging findings, and cognitive abilities between patients with SED, MDD, and controls over time. Associations between the symptom severity of MDD/SED and psychosocial variables, cognition, MRI, and the biomarkers will also be examined. The aim is to provide new diagnostic tools for differentiation between MDD and SED and guide individualized treatment based on underlying pathophysiology and cognitive function. All necessary competences for conducting this extensive study are represented within the research group. The PrimeCog study is unique in its comprehensive design, addressing knowledge gaps, and directly comparing these diagnoses over time in primary care, where patients are typically treated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research problems and specific questions Major depressive disorder (MDD) and stress induced exhaustion disorder (SED) are two growing public health concerns in primary care, causing individual suffering and affecting work productivity. MDD and SED call for different treatment strategies, but diagnosis differentiation pose several difficulties. Both conditions are linked to stress-related factors at work, and prescribed sick leave is a common treatment strategy. The main reasons for sick leave in DEP and UMS is cognitive difficulties, but no objective measures of cognition is used today. The aim of the PrimeCog project is to provide new diagnostic tools for differentiation between MDD and SED and guide individualized treatment based on cognitive function and underlying pathophysiology.

Data and method The project is a multicenter longitudinal, prospective research project on patients with newly diagnosed MDD or SED and healthy controls, n=100/group. The participants will be recruited at primary care centers. Data is collected through a digital cognitive test battery carried out at home, a questionnaire with screening scales and psychosocial risk factors, biomarkers in blood, saliva and hair, and a magnetic resonance imaging (MRI) of the brain. These procedures will be repeated after 12 and 24 months.

Societal relevance and utilization New diagnostic tools are needed for DEP and UMS in primary care to improve differential diagnosis and to individualize treatment in order to get the right intervention and treatment as quickly as possible. This could hypothetically contribute to shorter illness duration and reduce the length of sick leave. By investigating digital cognitive testing in primary care patients with MDD or SED, the PrimeCog project seeks to enhance diagnosis and follow-up which may prevent negative outcomes for individuals and benefit society by advancing mental health care as a whole. Digital cognitive testing is a new tool in primary care, and potentially both time- and cost-effective approach for objectively measuring cognitive symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mental Health Issue Cognitive Symptom Primary Health Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case1

Individuals diagnosed with major depressive disorder (MDD)

No interventions assigned to this group

Case2

Individuals diagnosed with stress induced exhaustion disorder (SED)

Cognitive Testing

Intervention Type DIAGNOSTIC_TEST

Digital Cognitive Testing performed at home.

Control

Healthy Controls (HC) (i.e. individuals without symptoms of MDD or SED)

Cognitive Testing

Intervention Type DIAGNOSTIC_TEST

Digital Cognitive Testing performed at home.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cognitive Testing

Digital Cognitive Testing performed at home.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. adults 18 to 65 years old;
2. fluent in Swedish;
3. corrected to normal vision and hearing;
4. (for cases), newly diagnosed with MDD or SED (i.e., received as new diagnosis at the visit to the physician) according to the diagnostic criteria from DSM-V (MDD) and the Swedish Board of Health and Welfare (SED)

Exclusion Criteria

1. already ongoing treatment for MDD/SED or previous diagnosis of MDD/SED within the last year;
2. history of serious mental illness (defined as mental illness that has required psychiatric in-patient care);
3. acute cerebrovascular event or severe head trauma in the last 6 months;
4. known cognitive impairment;
5. substance dependence, ongoing or past;
6. motor disability or impairment affecting interaction with the digital tests;
7. photosensitive epilepsy or -migraines.

For the MRI subgroup, any contraindication to MRI is an exclusion criterion.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Region Östergötland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hanna Israelsson Larsen

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hanna Israelsson Larsen, PhD

Role: PRINCIPAL_INVESTIGATOR

Region Ostergotland/Linkoping University

Anna Segernas, PhD

Role: PRINCIPAL_INVESTIGATOR

Region Ostergotland/Linkoping University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Region Ostergotland, primary care centrum

Linköping, Östergötland County, Sweden

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hanna Israelssion Larsen, PhD

Role: CONTACT

+46738317008

Anna Segernäs, PhD

Role: CONTACT

+46733641430

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hanna Israelsson Larsen, PhD

Role: primary

0738317008

Anna Segernas, PhD

Role: backup

+46733641430

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-05703-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Predictors of Cognitive Outcomes in Geriatric Depression
NCT05273996 ACTIVE_NOT_RECRUITING PHASE4
Precision Care for Major Depressive Disorder
NCT06580041 ENROLLING_BY_INVITATION PHASE4